natgillin/translations-raw huggingface dataset:
The presence of free Yttrium (90Y) chloride in the body after an inadvertent administration of Yttriga will lead to increased bone marrow toxicity and haematopoietic stern cell damage.
Prisotnost prostega itrijevega (90Y) klorida v telesu, po nenamernem dajanju zdravila Yttriga, bo povzročila povečano toksičnost za kostni mozeg in okvaro hematopoetskih matičnih celic.
The presence of genetic defects affecting ALK (‘ALK-positive’ status) has to be confirmed in advance by appropriate methods.
Prisotnost genskih okvar, ki vplivajo na anaplastično limfomsko kinazo (ALK-pozitivno stanje), je treba predhodno potrditi z ustreznimi metodami.
The presence of HACA may be associated with worsening of infusion or allergic reactions after the second infusion of subsequent courses.
Po drugi infuziji nadaljnjih ciklov so lahko HACA povezana z intenzivnejšimi z infuzijo povezanimi ali alergijskimi reakcijami.
The presence of hepatic impairment should not require a change in dosage.
Pri bolnikih z okvaro jeter odmerka ni treba prilagajati.
The presence of HLA-A*3101 allele may increase the risk for carbamazepine induced cutaneous reactions (mostly less severe) from 5.0% in general population to 26.0% among subjects of European ancestry, whereas its absence may reduce the risk from 5.0% to 3.8%.
Prisotnost alela HLA-A*3101 lahko poveča tveganje za kožne reakcije, ki jih povzroči karbamazepin (običajno manj resne) od 5,0 % pri splošni populaciji do 26,0 % pri potomcih evropskega porekla, medtem ko lahko njegova odsotnost tveganje zmanjša s 5,0 % na 3,8 %.
The presence of hypoalbuminaemia was associated with an increased risk of prolongation of the QTc interval (see section 4.4).
Prisotnost hipoalbuminemije je bila povezana z višjim tveganjem podaljšanja intervala QTc (glejte poglavje 4.4).
The presence of lesions, conditions, procedures and/or pharmacological treatment (such as NSAIDs, antiplatelets, SSRIs and SNRIs, see section 4.5), which signficantly increase the risk of major bleeding requires a careful benefit-risk assessment.
Pri poškodbah, bolezenskih stanjih, postopkih ali zdravljenju z zdravili (kot so NSAR, antitrombotiki, SSRI in SNRI, glejte poglavje 4.5), ki pomembno povečajo nevarnost velike krvavitve, je treba natančno presoditi o koristi in tveganju.
The presence of M184V with K65R does give rise to cross- resistance between abacavir, tenofovir, didanosine and lamivudine, and M184V with L74V gives rise to cross-resistance between abacavir, didanosine and lamivudine.
Vendar prisotnost M184V s K65R povzroči navzkrižno odpornost med abakavirjem, tenofovirjem, didanozinom in lamivudinom ter prisotnost M184V z L74V povzroči navzkrižno odpornost med abakavirjem, didanozinom in lamivudinom.
The presence of maternal antibodies against Aujeszky’s disease virus may have a negative influence on the result of vaccination.
Prisotnost maternalnih protiteles proti Aujeszkyjevi bolezni lahko negativno učinkuje na rezultat cepljenja.
The presence of maternally derived antibodies against infectious bovine rhinotracheitis virus may interfere with the vaccination and requires an appropriate vaccination regimen.
Prisotnost maternalnih protiteles proti IBR virusu lahko vpliva na uspešnost cepljenja, zato je potreben poseben program cepljenja
The presence of osteoblastic metastases which take up technetium (99mTc)-labelled biphosphonates should be confirmed prior to therapy.
Pred uvedbo zdravljenja moramo potrditi prisotnost osteoblastnih metastaz, ki kopičijo s tehnecijem (99mTc) označene bifosfonate.
The presence of persistent anti- natalizumab antibodies increased natalizumab clearance approximately 3-fold, consistent with reduced serum natalizumab concentrations observed in persistently antibody-positive patients, (see section 4.8).
Prisotnost obstojnih proti-natalizumabnih protiteles je povečala očistek natalizumaba za približno trikrat, kar je v skladu z zmanjšanjem serumskih koncentracij natalizumaba, ugotovljenih pri bolnikih z obstojnimi proti-natalizumabnimi protitelesi (glejte poglavje 4.8).
The presence of renal impairment should not require a change in dosage.
Pri bolnikih z okvaro ledvic odmerka ni treba prilagajati.
The presence of the disease in the herd should be established before metaphylactic treatment.
Pred preve metafilaktično ntivno uporabo je potrebno dokazati prisotnost bolezni v čredi.
The presence of the disease in the herd should be established before metaphylaxis.
Preden začnete z metafilakso, morate ugotoviti prisotnost bolezni v čredi.
The presence of the genetic changes affecting ALK (‘ALK-positive’ status) or ROS1 (‘ROS1-positive’ status) has to be confirmed in advance by appropriate methods.
Prisotnost genske spremembe, ki vpliva na anaplastično limfomsko kinazo (ALK-pozitivno stanje) ali ROS1 (ROS1-pozitivno stanje), je treba predhodno potrditi z ustreznimi metodami.
The presence of these metabolites in urine together with the high total body clearance and low urinary excretion of unchanged drug in the urine (~4% of the dose) indicate that decitabine is appreciably metabolized in vivo.
Prisotnost teh presnovkov v urinu, visoka vrednost celotnega očistka iz telesa in majhen obseg izločanja nespremenjene učinkovine z urinom (~4% odmerka) kažejo, da se in vivo decitabin v precejšnji meri presnovi.
The presentation of the safety profile is based on the experience with Ultibro Breezhaler and the individual components.
Predstavitev varnostnih lastnosti temelji na izkušnjah z uporabo zdravila Ultibro Breezhaler in njegovih posameznih učinkovin.
The presentation of the safety profile is based on the experience with Ulunar Breezhaler and the individual components.
Predstavitev varnostnih lastnosti temelji na izkušnjah z uporabo zdravila Ulunar Breezhaler in njegovih posameznih učinkovin.
The presentation of the safety profile is based on the experience with Xoterna Breezhaler and the individual components.
Predstavitev varnostnih lastnosti temelji na izkušnjah z uporabo zdravila Xoterna Breezhaler in njegovih posameznih učinkovin.
The presented safety information is derived principally from paediatric patients.
Predstavljeni varnostni podatki so bili v glavnem zbrani na podlagi pediatričnih bolnikov.
The preservative in NEVANAC, benzalkonium chloride can discolour soft lenses and may cause eye irritation and corneal side effects (eye surface problems).
Konzervans v zdravilu NEVANAC benzalkonijev klorid lahko obarva mehke kontaktne leče in povzroči draženje oči ter neželene učinke na roženici (težave na površini očesa).
The preservative in NEVANAC, bezalkonium chloride, can discolour soft lenses and may cause eye irritation and corneal side effects (eye surface problems).
Konzervans v zdravilu NEVANAC benzalkonijev klorid lahko obarva mehke kontaktne leče in povzroči draženje oči ter neželene učinke na roženici (težave na površini očesa).
The prespecified net clinical benefit (primary efficacy outcome plus major bleeding events) of the pooled analysis was reported with a hazard ratio of 0.771 ((95% CI: 0.614 – 0.967), nominal p value p= 0.0244).
O vnaprej določeni čisti klinični koristi zdravljenja (primarni izid učinkovitosti in velike krvavitve) analize zbranih podatkov so poročali z razmerjem tveganja 0,771 ((95 % IZ: 0,614 - 0,967), nominalna vrednost p = 0,0244).
The prespecified net clinical benefit (primary efficacy outcome plus major bleeding events) of the pooled analysis was reported with a hazard ratio of 0.771 ((95% CI: 0.614 – 0.967), nominal p value p= 0.0244).
O vnaprej določeni čisti klinični koristi zdravljenja (primarni izid učinkovitosti in velike krvavitve) analize zbranih podatkov so poročali z razmerjem tveganja 0,771 ((95 % IZ: 0,614 – 0,967), nominalna vrednost p = 0,0244).
The prespecified net clinical benefit (primary efficacy outcome plus major bleeding events) was reported with a hazard ratio of 0.67 ((95% CI: 0.47 - 0.95), nominal p value p=0.027) in favour of rivaroxaban.
Vnaprej določena čista klinična korist zdravljenja (primarni izid učinkovitosti in velike krvavitve) je bila v korist rivaroksabana z razmerjem tveganja 0,67 ((95 % IZ: 0,47 - 0,95), nominalna vrednost p = 0,027).
The prespecified net clinical benefit (primary efficacy outcome plus major bleeding events) was reported with a hazard ratio of 0.67 ((95% CI: 0.47 – 0.95), nominal p value p=0.027) in favour of rivaroxaban.
Vnaprej določena čista klinična korist zdravljenja (primarni izid učinkovitosti in velike krvavitve) je bila v korist rivaroksabana z razmerjem tveganja 0,67 ((95 % IZ: 0,47 - 0,95), nominalna vrednost p = 0,027).
The prespecified net clinical benefit (primary efficacy outcome plus major bleeding events) was reported with a hazard ratio of 0.849 ((95% CI: 0.633 - 1.139), nominal p value p= 0.275).
O predhodno določeni čisti klinični koristi (izid primarne učinkovitosti in velike krvavitve) so poročali z razmerjem tveganja 0,849 ((95 % IZ: 0,633 - 1,139), nominalna vrednost p = 0,275).
The pressure regulator should be used in accordance with the manufacturer’s instruction.
Regulator tlaka morate uporabljati v skladu z navodili izdelovalca.
The pressure regulator should be used in accordance with the manufacturer’s instructions.
Regulator tlaka morate uporabljati v skladu z navodili izdelovalca.
The PREVAIL study enrolled chemotherapy-naive patients; whereas the AFFIRM study enrolled patients who had received prior docetaxel.
V študijo PREVAIL so bili vključeni bolniki, ki se predhodno še niso zdravili s kemoterapijo, medtem ko so bili v študijo AFFIRM vključeni bolniki, ki so se predhodno zdravili z docetakselom.
The prevalence of CAN/IFTA at Year 1 in Studies 1 and 2, was numerically lower with belatacept than ciclosporin (~ 9.4% and 5%, respectively).
V Študijah 1 in 2 je bila prevalenca kronične nefropatije alogenskega presadka/intersticijske fibroze in tubularne atrofije v 1. letu numerično manjša pri uporabi belatacepta kot pri uporabi ciklosporina (približno 9,4 % in 5 %).
The prevalence of congenital malformations after ART may be slightly higher than after spontaneous conceptions.
Prevalenca kongenitalnih malformacij po oploditvah z biomedicinsko pomočjo (Assisted Reproductive Technology – ART) je lahko rahlo višja kot po spontanem spočetju.
The prevalence of ectopic pregnancy after ART was reported to be higher than in the general population.
Po ART so poročali o višji prevalenci zunajmaternične nosečnosti v primerjavi s splošno populacijo.
The prevalence of HLA-B*1502 carrier is about 10% in Han Chinese and Thai populations.
Prevalenca nosilcev HLA-B*1502 je približno 10 % populacije Han kitajske in tajske narodnosti.
the prevention of acute nausea and vomiting associated with highly emetogenic cancer chemotherapy, the prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy.
preprečevanje akutne navzee in bruhanja, povezanih z visoko emetogenimi kemoterapijami pri zdravljenju raka, preprečevanje slabosti in bruhanja, povezanih z zmerno emetogenimi kemoterapijami pri zdravljenju raka.
The previous day’s patch must be removed before applying a new one every day (see section 4.9).
Vsak dan je treba pred nameščanjem novega obliža odstraniti obliž predhodnega dne (glejte poglavje 4.9).
The Prezista 800 milligram tablets are available in packs containing one bottle or three bottles per carton.
Zdravilo PREZISTA 800 mg filmsko obložene tablete je na voljo v škatlah, ki vsebujejo 1 ali 3 plastenke.
The primary active metabolite comprises 23 to 37% of the total exposure.
Primarni aktivni presnovek predstavlja od 23 do 37 % celotne izpostavljenosti.
The primary adverse effect of oritavancin administration to rats and dogs was a dose related accumulation of eosinophilic granules in tissue macrophages including hepatocytes, renal cortical epithelial cells, adrenal cells and macrophages of the reticulo endothelial system.
Primarni neželeni učinek pri dajanju oritavancina podganam in psom je bilo od odmerka odvisno kopičenje eozinofilnih granulo v tkivnih makrofagih, vključno s hepatociti, ledvičnimi kortikalnnimi epitelijskimi celicami, celicami nadledvične žleze in makrofagi retikuloendotelijskega sistema.
The primary aim of demonstrating non-inferiority of insulin glargine to NPH in all hypoglycaemia was not met and there was a trend to an increase of hypoglycemic events with insulin glargine [insulin glargine: NPH rate ratio (95% CI) = 1.18 (0.97-1.44)].
Primarni cilj, dokazati neinferiornost insulina glargin v primerjavi z insulinom NPH v zvezi z hipoglikemijami, ni bil dokazan – opazen je bil trend povečanja hipoglikemičnih dogodkov z insulinom glargin [razmerje insulin glargin : NPH (95 % IZ) = 1,18 (0,97-1,44)].
The primary analyses of efficacy were performed on the ATP cohort for efficacy and the TVC.
Primarne analize učinkovitosti so naredili v kohorti PP glede učinkovitosti in v TVC.
The primary analyses of efficacy, with respect to vaccine HPV types (HPV 6, 11, 16, and 18), were conducted in the per-protocol efficacy (PPE) population (i.e. all 3 vaccinations within 1 year of enrollment, no major protocol deviations and naïve to the relevant HPV type(s) prior to dose 1 and through 1 month Postdose 3 (Month 7)).
Primarne analize učinkovitosti, ki se nanašajo na tipe HPV v cepivu (tip HPV 6, 11, 16 in 18), so bile izvedene v PPE (per-protocol efficacy) populaciji (tj. vsa 3 cepljenja v 1 letu po vključitvi, brez večjih odklonov od protokola študije in neizpostavljenost zadevnemu tipu (zadevnim tipom) HPV pred 1. odmerkom in tekom 1 meseca po 3. odmerku (7. mesec).
The primary analysis of the primary endpoint PFS is based on disease assessment by independent radiological review in the entire study population (treatment naïve and cytokine pre-treated).
Primarna analiza primarnega opazovanega dogodka to je čas preživetja brez napredovanja bolezni temelji na neodvisni presoji radiološkega pregleda celotne študijske populacije (predhodno še nezdravljeni bolniki in bolniki, ki so se predhodno že zdravili s citokini).
The primary analysis of this study was performed on the population of all patients randomly assigned to a treatment arm who received study drug (randomised and treated).
Prvotna analiza učinkovitosti je bila osnovana na NZ populaciji.
The primary and secondary endpoints evaluated the occurrence of one or more skeletal related events (SREs).
Primarni in sekundarni opazovani dogodek sta ocenjevala pojav enega ali več skeletnih dogodkov (SRE – skeletal related events).
The primary biliary, faecal and urinary metabolites in both the rat and the dog were identified as the demethylated spinosyns, glutathione conjugates of the parent compounds and N- demethylated spinosyns A and D. Excretion is primarily via the bile and faeces, and also to a lesser extent in the urine.
Glavne presnovke v žolču, blatu in urinu pri podganah in psih so opredelili kot demetilirane spinosine, glutationske konjugate starševskih spojin in N-demetilirana spinosina A in D. Glavna pot izločanja je z žolčem in blatom, v manjši meri pa tudi z urinom.
The primary biotransformation pathway for teriflunomide is hydrolysis with oxidation being a minor pathway.
Primarna pot biotransformacije teriflunomida je hidroliza, manj prisotna pa je oksidacija.
The primary biotransformation pathway for teriflunomide is hydrolysis, with oxidation being a minor pathway.
Primarna pot biotransformacije teriflunomida je hidroliza, manj pomembna presnovna pot je oksidacija.
The primary clinical evidence for the efficacy of cangrelor is derived from CHAMPION PHOENIX, a randomised, double-blind study comparing cangrelor (n=5472) to clopidogrel (n=5470), both given in combination with aspirin and other standard therapy, including unfractionated heparin (78%), bivalirudin (23%), LMWH (14%) or fondaparinux (2.7%).
Primarni klinični dokaz za učinkovitost kangrelorja je izpeljan iz študije CHAMPION PHOENIX, ki je bila randomizirana, dvojno slepa študija primerjave kangrelorja (n = 5.472) s klopidogrelom (n = 5.470), oba uporabljena v kombinaciji z acetilsalicilno kislino ali drugim standardnim zdravljenjem, vključno z nefrakcioniranim heparinom (78 %), bivalirudinom (23 %), nizkomolekularnim heparniom (14 %) ali fondaparinuksom (2,7 %).
The primary complications of overdose are bone marrow suppression and mucositis.
Kot pomembnejši posledici prevelikega odmerjanja lahko pričakujemo predvsem supresijo kostnega mozga in mukozitis.
The primary efficacy criterion was superiority of the combination fenofibrate 145 and simvastatin 20 mg versus simvastatin 40 mg on TG decrease and HDL-C increase and non-inferiority for LDL-C decrease at 12 weeks.
Primarno merilo učinkovitosti je bila boljša učinkovitost kombinacije fenofibrata 145 mg in simvastatina 20 mg v primerjavi s simvastatinom 40 mg pri znižanju TG in zvišanju HDL-holesterola ter neinferiornost pri znižanju LDL-holesterola po 12 tednih.
The primary efficacy endpoint defined for this study, was a combined response criterion consisting of improvement in exercise capacity (6-minute walk test) at 12 weeks by at least 10% versus baseline, and improvement by at least one NYHA class at 12 weeks versus baseline, and no deterioration of pulmonary hypertension or death at any time before 12 weeks.
V tej študiji je bila primarna učinkovitost opredeljena kot kombinacija kriterijev odziva, ki jo sestavljajo izboljšanje telesne zmogljivosti (6-minutni test hoje) po 12 tednih za najmanj 10 % v primerjavi z izhodiščno vrednostjo in izboljšanje za vsaj en razred po klasifikaciji NYHA po 12 tednih glede na izhodiščno vrednost ter odsotnost primerov napredovale pljučne hipertenzije ali smrti kadarkoli pred iztekom 12 tednov.
The primary efficacy endpoint evaluated the effect of ataluren on ambulation as assessed by the change in distance (6MWD) walked during a 6MWT.
Primarni opazovani dogodek za oceno učinkovitosti je bil učinek atalurena na mobilnost, ki so ga ovrednotili glede na spremembo v razdalji, prehojeni v 6-minutnem testu hoje.
The primary efficacy endpoint for these studies was overall response rate (ORR), defined as the proportion of patients with best response of complete response (CR) or partial response (PR) confirmed by repeat assessments performed not less than 4 weeks after the criteria for response was first met.
Primarni cilj opazovanja učinkovitosti v teh študijah je bila celokupna stopnja odziva (overall response rate, ORR), ki je bila opredeljena kot delež bolnikov, katerih najboljši odziv je bil popolni odziv (complete response, CR) ali delni odziv (partial response, PR), potrjen z meritvijo, ki so jo ponovili najmanj 4 tedne po tem, ko je bolnik prvič dosegel kriterije za odziv.
The primary efficacy endpoint for this study was the achievement and maintenance of confirmed HIV- 1 RNA concentrations < 400 copies/ml over 48 weeks.
Primarni cilj učinkovitosti pri tej študiji je bilo doseganje in vzdrževanje potrjenih koncentracij HIV-1 RNA < 400 kopij/ml v 48 tednih.
The primary efficacy endpoint in all four studies was the proportion of patients in each treatment group who achieved the PASI 75 (i.e., at least a 75% improvement in the Psoriasis Area and Severity Index score from baseline) at 12 weeks.
Primarni opazovani dogodek učinkovitosti v vseh štirih študijah je bil tisti delež bolnikov v vsaki zdravljeni skupini, ki je po 12 tednih dosegel PASI 75 (tj. vsaj 75 % izboljšanje indeksa PASI – Psoriasis Area and Severity Index; indeks površine in izrazitosti psoriaze - v primerjavi z izhodiščem).
The primary efficacy endpoint in all four studies was the proportion of patients in each treatment group who achieved the PASI 75 (i.e., at least a 75% improvement in the Psoriasis Area and Severity Index score from baseline) at 12 weeks.
Primarni opazovani dogodek učinkovitosti v vseh štirih študijah je bil tisti delež bolnikov v vsaki zdravljeni skupini, ki je po 12 tednih dosegel PASI 75 (tj. vsaj 75-% izboljšanje indeksa PASI – Psoriasis Area and Severity Index; indeks površine in izrazitosti psoriaze - v primerjavi z izhodiščem).
The primary efficacy endpoint in all of the phase 3 studies was the mean percent reduction from baseline in LDL-C at week 24 as compared to placebo or ezetimibe.
Primarni opazovani dogodek učinkovitosti v vseh študijah 3. faze je bilo povprečno odstotno znižanje LDL- H od izhodišča do 24. tedna v primerjavi s placebom ali ezetimibom.
The primary efficacy endpoint in both studies was objective response rate (ORR) according to RECIST.
Primarni, na učinkovitost nanašajoči se opazovani dogodek v obeh študijah je bil objektivni odziv na zdravljenje (ORR – Objective Response Rate) po merilih RECIST.
The primary efficacy endpoint in both studies was the absolute change from baseline in ppFEV1 at week 24.
Primarno končno stanje učinkovitosti v obeh študijah je bila absolutna sprememba ppFEV1 od izhodišča v 24. tednu.
The primary efficacy endpoint in both studies was time to progression (TTP).
Primarni končni cilj učinkovitosti v obeh študijah je bil čas do napredovanja bolezni (TTP – time to progression).
The primary efficacy endpoint in CP-CML was major cytogenetic response (MCyR), which included complete and partial cytogenetic responses (CCyR and PCyR).
Primarni opazovani dogodek učinkovitosti pri bolnikih s CP-KML je bil bistven citogenetski odgovor (MCyR, major cytogenetic response), ki je vključeval celovit (CCyR, complete cytogenetic response) ali delni citogenetski odgovor (PCyR, partial cytogenetic response).
The primary efficacy endpoint in Study MCL-002 was progression-free survival (PFS).
Primarni učinkovitostni cilj študije MCL-002 je bilo preživetje brez napredovanja bolezni (PFS)
The primary efficacy endpoint in Study MCL-002 was progression-free survival (PFS).
Primarni učinkovitostni cilj študije MCL-002 je bilo preživetje brez napredovanja bolezni (PFS).
The primary efficacy endpoint in the study was progression free survival (PFS).
Primarni cilj učinkovitosti v študiji je bilo preživetje brez napredovanja bolezni (PFS - progression free survival ).
The primary efficacy endpoint in the study was progression free survival (PFS).
Primarni cilj učinkovitosti v študiji je bilo preživetje brez napredovanja bolezni (PFS - progression free survival).
The primary efficacy endpoint in the study was progression free survival (PFS).
Primarni cilj učinkovitosti v študiji je bilo preživetje brez napredovanja bolezni (PFS).
The primary efficacy endpoint of the study was the major cytogenetic response (MCyR) rate at week 24 in patients with imatinib-resistant CP CML previously treated with only one prior TKI (imatinib).
Primarni, na učinkovitost nanašajoči se opazovani dogodek je bil pomembni citogenetični odziv (MCyR - major cytogenetic response) ob 24. tednu pri bolnikih s KML v kronični fazi, neodzivnih na imatinib, ki so bili predhodno zdravljeni le z enim TKI (imatinib).
The primary efficacy endpoint of the study was TTP, defined as the time from randomization to first documentation of objective tumour progression.
Primarna končna točka učinkovitosti v tej študiji je bil TTP, opredeljen kot čas od randomizacije do prvega dokumentiranega objektivnega napredovanja tumorja.
The primary efficacy endpoint of this study was ORR.
Primarna končna točka učinkovitosti v tej študiji je bil ORR.
The primary efficacy endpoint was a composite endpoint (SLE Responder Index) that defined response as meeting each of the following criteria at Week 52 compared with baseline:
Primarni opazovani dogodek učinkovitosti je bil sestavljeni dogodek (indeks odziva SLE – SLE Responder Index [SRI]), ki je odziv opredelil kot izpolnitev vsakega od naslednjih meril 52. teden v primerjavi z izhodiščem:
The primary efficacy endpoint was a two-component composite score based on the sum of the ranks of the change from baseline to the end of the study in the distance walked during six minutes (6-minute walk test or 6MWT) as a measure of endurance, and % predicted forced vital capacity (FVC) as a measure of pulmonary function.
Primarni cilj študije je bil dvokomponentni rezultat, ki je temeljil na vsoti ranga spremembe razdalje, prehojene v 6 minutah (6-minutni preizkus s hojo ali 6MWT – „6 minute walk test“) kot mere za vzdržljivost in odstotka pričakovane forsirane vitalne kapacitete (FVK) kot mere za delovanje pljuč.